Estrogen Receptor Dependent Inhibitors of NF-κB Transcriptional Activation-1 Synthesis and Biological Evaluation of Substituted 2-Cyanopropanoic Acid Derivatives: Pathway Selective Inhibitors of NF-κB, a Potential Treatment for Rheumatoid Arthritis

Citations Over Time

Abstract

Pathway selective ligands of the estrogen receptor inhibit transcriptional activation of proinflammatory genes mediated by NF-kappaB. Substituted 2-cyanopropanoic acid derivatives were developed leading to the discovery of WAY-204688, an orally active, pathway selective, estrogen receptor dependent anti-inflammatory agent. This propanamide was shown to be orally active in preclinical models of inflammatory diseases, such as rheumatoid arthritis, without the proliferative effect associated with traditional estrogens.

Related Papers

• → Estrogen Up-regulates ATBF1 Transcription but Causes Its Protein Degradation in Estrogen Receptor-α-positive Breast Cancer Cells(2011)30 cited
• → Estrogen-induced downregulation of TASK-1 expression through estrogen receptor β in N2A cells(2021)1 cited
• → Estrogen and estrogen receptors of breast cancer(1975)3 cited
• Expression profiling of genes controlled by estradiol (E2) and/or nuclear estrogen receptors ER α and ER β(2009)
• Effects of estrogen on estrogen receptors in myocardium of ovariectomized female rats(2008)